*Note
on course proficiencies*
YEAR 4
SEMESTER 1 - 2 - 3
Infectious Disease
PHAR 5681
Course Description:
A structured pharmacy experience in an institutional setting dealing
with patients with infectious diseases.
Cr. 6. (0-18)
Prerequisite:
Fourth year standing in the College of Pharmacy or consent of
the instructor.
Course Proficiencies:
The student will be able to:
1. Differentiate a Gram stain to assess the
potential infecting organism in a patient.
2. Prepare a therapeutic presentation to educate infectious diseases
fellows and faculty about a specific therapeutic topic.
3. Establish a therapeutic plan for the treatment of the febrile
neutropenic patient.
4. Based on site location in solid tumor patients, develop an
empiric treatment plan for the three most commonly encountered
organisms.
5. Develop a treatment pathway for the use of lipid amphotericin
products in patients with suspected aspergillosis to assess its
use compared to conventional amphotericin.
6. Establish a monitoring protocol for the use of parenteral vancomycin
in solid tumor patients to assess its rational use.
7. Evaluate the impact of VRE in the stool of cancer patients
to assess the impact on infection control .
8. Perform an analysis of the CSF profile of a suspected meningitis
patient to assess the appropriate empiric therapy to be instituted.
9. Perform an analysis of a U/A to assess the need for treatment
of funguria.
10. Read an antibiogram for a specific patient to assess the proper
anti-infective choices from the test.
11. Determine the use of non-steroidal anti-inflammatory agents
in cancer patients to assess the probability of tumor fever vs.
infection.
12. Outline a treatment plan for the institution of therapy in
a centrally catheterized patient to assess proper prescribing
habits.
13. Establish appropriate monitoring parameters for all patients
to assess therapeutic outcomes.
14. Analyze sputum and BAL specimen determinations to assess the
need for and against therapy (infection vs. colonization).
15. Electronically survey cancer patient lab profiles to assess
the need anti-infective therapy adjustments based on organ function.
16. Determine an aminoglycoside dose regimen for a renally-impaired
cancer patient using pharmacokinetic principles to assess patient
response.
17. Determine an aminoglycoside dose regimen for a renally-impaired
cancer patient using pharmacodynamic principles to assess patient
response.
18. Determine the difference in potential causes of community-acquired
versus hospital acquired pneumonia in solid tumor patients to
assess the difference in empiric therapy approaches.
